Patents by Inventor Shamina Rangwala

Shamina Rangwala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230322888
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • Patent number: 11713345
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 1, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
  • Publication number: 20220089669
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: October 22, 2019
    Publication date: March 24, 2022
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • Publication number: 20190234935
    Abstract: A novel receptor for GDF15 was identified (GFRAL), as well as the use of this receptor in the identification or screening of GDF15 agonists or antagonists. These agonist or antagonist compounds may be used to either potentiate or suppress GDF15-like effects, respectively, at the cellular and organism levels, and may be used in treatment of metabolic diseases, including obesity, type 2 diabetes, hyperglycemia, hyperinsulinemia, dyslipidemia, diabetic nephropathy, or anorexia.
    Type: Application
    Filed: October 11, 2017
    Publication date: August 1, 2019
    Inventors: Anthony Armstrong, Stephen Beck, Jose Antonio Chavez, Chen-Ni Chin, Thai Dinh, Jennifer Furman, Matt Husovsky, Xiefan Lin-Schmidt, Shannon Mullican, Shamina Rangwala, Vicki South
  • Patent number: 10336812
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Publication number: 20170327560
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 16, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina Rangwala, Shannon Mullican, Jose Antonio Chavez